Home › Funds › Perpetual Ltd › ABT

Perpetual Ltd position in ABT

ABBOTT LABORATORIES · Health Care

Perpetual Ltd reported holding 444,048 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$43.9M, representing 0.67% of its reported portfolio and ranking #40 among its reported holdings. Perpetual Ltd has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)444.05K sh
Reported value held$43.89M
Portfolio Weight0.67%
First reportedQ3 2023
Last changeReduce
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Perpetual Ltd's ABT position evolved

Perpetual Ltd first disclosed a stake in ABT in Q3 2023 at 8,571 shares (US$830K). The position peaked in Q3 2026 at 444,048 shares, worth US$43.9M. Across 13 filings, Perpetual Ltd increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 444,048 shares valued at US$43.9M — a reduction of -26,238 shares quarter over quarter.. Notable position changes include a 438% increase in Q2 2024 (shares rose 10% over the following quarter), a 77% trim in Q3 2024 (shares were roughly flat over the following quarter), a 4290% increase in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 8.57K $830.06K New
Q4 2023 8.10K $891.57K Reduce
Q1 2024 8.10K $919.19K Hold
Q2 2024 43.58K $4.53M Add
Q3 2024 9.90K $1.13M Reduce
Q4 2024 9.90K $1.12M Hold
Q1 2025 9.90K $1.31M Hold
Q2 2025 7.40K $1.01M Reduce
Q3 2025 6.85K $917.89K Reduce
Q4 2025 8.78K $1.10M Add
Q1 2026 10.71K $1.10M Add
Q2 2026 470.29K $42.67M Add
Q3 2026 444.05K $43.89M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Perpetual Ltd held ABT?

Perpetual Ltd has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Perpetual Ltd's current position in ABT?

As of Q3 2026, Perpetual Ltd holds 444.05K shares of ABT (ABBOTT LABORATORIES), valued at $43.89M, representing 0.67% of its reported portfolio and ranking #40.

Has Perpetual Ltd been buying or selling ABT?

In the latest 13F filing (Q3 2026), Perpetual Ltd reduced its position in ABT. The position peaked in Q3 2026 at 444.05K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.